Loading...
An FDA advisory committee recently voted 8 to 7, with one abstention, to recommend that stimulant medications prescribed for attention deficit hyperactivity disorder (ADHD) carry a strong “black box” warning about potential cardiovascular risks. The vote was reported in the February 10, 2006, edition of the Wall Street Journal. The committee also recommended that prescriptions for stimulant medications should include a patient guide that reviews the evidence for potential cardiac risk. The FDA is reviewing the committee’s recommendations.
The advisory panel based its recommendations on data from children younger than 18 years, including reports of 7 sudden deaths associated with methylphenidate use and 12 deaths associated with amphetamine u…